Kenjockety Biotechnology, Inc.

Kenjockety Biotechnology is developing a new family of bispecific antibodies (BsAbs) to address the significant unmet need of drug resistance in patients with cancer. Our proprietary BASE ™ Platform is creating an extensive pipeline of new therapeutics by pairing our foundational antibodies that target Efflux Pumps (EPs) with antibodies to known Tumor Associated Antigen (TAA) targets, to construct BsAbs that more effectively target tumor cells versus normal cells. Efflux Pumps are complex membrane-spanning proteins that expel cellular toxins, metabolites, and also anti-cancer agents. EP overexpression on cancer cells leads to drug resistance and poor prognosis. Prior attempts to address EP-related drug resistance focused on the use of small molecules. These efforts were unsuccessful largely due to lack of tumor specificity resulting in toxicity or other complications inherent in the small molecule approach. Kenjockety's proprietary approach develops BsAbs engineered to be highly specific to cancer cells. We have generated impressive in vivo proof of concept data for efficacy across multiple tumor models that show potential for both single agent and combination approaches. Additional data with our lead molecule shows good safety properties, including results from a substantial non-GLP, non-human primate study. Evidence for drug resistance due to EP overexpression exists in nearly all solid tumors as well as in hematologic malignancies. An estimated 25% of all patients with cancer will receive chemotherapy as part of their treatment and as many as 80% will develop drug resistance. Key upcoming milestones include selecting our lead product candidate and completing the IND enabling studies needed to initiate clinical studies. We also anticipate advancing our pipeline by conducting in vivo testing for multiple new BsAbs that pair different EPs and TAAs.